EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Flow cytometric detection of activated mouse integrin αIIbβ3 with a novel monoclonal antibody

Wolfgang Bergmeier, Valerie Schulte, Gero Brockhoff, Ulrich Bier, Hubert Zirngibl, Bernhard Nieswandt

Cytometry · 2002-06 · 48 (2) · 80-86

DOI: 10.1002/cyto.10114 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Integrin αIIbβ3 mediates platelet adhesion and aggregation and plays a crucial role in thrombosis and hemostasis. αIIbβ3 is expressed in a low affinity state on resting platelets. Upon platelet activation, αIIbβ3 shifts to a high affinity conformation that efficiently binds its ligands. On human platelets, the high affinity conformation of αIIbβ3 is detected by the monoclonal antibody (mAb), PAC‐1. However, a reagent with binding specificity to high affinity mouse αIIbβ3 has not been described so far. Methods A novel rat mAb directed against mouse αIIbβ3 (JON/A) was generated and characterized. JON/A was conjugated with fluorescein isothiocyanate (JON/A FITC ) or with R‐phycoerythrin (JON/A PE ) and used for flow cytometric analysis of mouse platelets. Results Although JON/A FITC bound to resting and activated platelets, virtually no binding of the larger JON/A PE to resting platelets was detectable. However, strong binding of JON/A PE occurred on platelet activation in a dose‐dependent manner. Binding of JON/A PE required extracellular free calcium and was irreversible, thereby stabilizing the high affinity conformation of αIIbβ3. Conclusion JON/A PE is the first tool for direct assessment of integrin αIIbβ3 activation in mice. Furthermore, JON/A FITC and JON/A PE provide the first examples of fluorescent antibody derivatives with identical antigenic specificitiy that allow the discrimination between the resting and the activated state of an integrin. Cytometry 48:80–86, 2002. © 2002 Wiley‐Liss, Inc.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →